-
The success of the CRISPR cancer trial paved the way for personalized treatment
Time of Update: 2022-12-04
"After a series of analyses to confirm their findings, validate their predictions, and design a protein called the T cell receptor, which recognizes tumor mutations, the researchers took blood samples from each participant and inserted the receptor into their T cells using CRISPR genome editing.
-
Science Translational Medicine: CRISPR gene-edited universal CAR-T, clinical trial results for the treatment of childhood leukemia released
Time of Update: 2022-11-04
The research team used next-generation CRISPR-Cas9 gene editing technology to knock out TRAC and CD52 of CAR19 T cells, construct a universal CAR-T cell, TT52CAR19 T cells, and conducted a phase 1 clinical trial for the treatment of childhood B-cell acute lymphoblastic leukemia (B-ALL).
-
Rheumatology: application experience of mycophenolate mofetil in adolescent idiopathic inflammatory myopathy
Time of Update: 2022-08-19
1093/rheumatology /keac404 Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in the treatment of juvenile idiopathic inflammatory myopathy (JIIM) .
1093/rheumatology /keac404 Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in the treatment of juvenile idiopathic inflammatory myopathy (JIIM) .
-
Cinda failed to introduce ISAC drug clinical research and development, Bolt stock price plummeted 56
Time of Update: 2021-12-30
As a new immunotherapy, the Boltbody ISAC platform consists of three main components: tumor-targeting antibodies, non-degradable linkers, and proprietary immunostimulants (TLR 7/8 agonists) used to activate the patient’s innate immune system .
-
Eur J Pharm Biopharm: Improving the negative effects of the new Amodafinil microneedle patch on sleep deprivation
Time of Update: 2021-11-13
Amodafinil microneedle can significantly improve the cognitive level of sleep-deficient rats, thereby reducing the various adverse effects of sleep deprivation on mice.
-
Suitable for a wide range of tumor types, innovative peptide-conjugated drugs to enhance the effect of immunotherapy
Time of Update: 2021-10-22
▲The mechanism of using low pH insert peptides to deliver anti-cancer drugs to tumor cells (picture source: Cybrexa official website)The researchers used a mouse model of colorectal cancer to further evaluate the effect of CBX-12 on the efficacy of PD-1 and CTLA4 immune checkpoint inhibitors .
-
CRISPR-edited stem cell therapy for the treatment of acute myeloid leukemia obtains FDA fast-track qualification
Time of Update: 2021-09-19
S. FDA has granted its engineered hematopoietic stem cell (eHSC) candidate drug VOR33 fast track qualification for the treatment of acute myeloid leukemia (AML) .
Therefore, the hematopoietic stem cells infused back into the patient will produce healthy new cells that do not express CD33 protein .
com/news-releases/news-release-details/vor33-granted-us-fda-fast- track-designation-aml
-
Lower dose
Time of Update: 2021-08-10
Click on the picture to register now July 10, 2021/eMedClub News/--Recently, ASC Therapeutics announced that the US FDA has approved its research second-generation gene therapy ASC618 IND application for the treatment of severe or moderate A hemophilia .
-
Innovent's PI3Kδ inhibitor Parsaclisib was approved as a breakthrough therapy drug by CDE for the treatment of relapsed or refractory follicular lymphoma
Time of Update: 2021-04-14
At the 62nd American Annual Meeting of Hematology (ASH) in 2020, Incyte reported the data of a clinical study of Parsaclisib in the treatment of relapsed/refractory follicular lymphoma.
Incyte also plans to conduct trials to evaluate parsaclisib combined with tafasitamab in the treatment of non-Hodgkin's lymphoma (NHL) and chronic myeloid leukemia (CLL).
-
Nefecon, a new drug for primary IgA nephropathy, applies for listing in the United States
Time of Update: 2021-03-27
The Swedish biopharmaceutical company Calliditas Therapeutics recently announced that it has submitted a new drug application (NDA) for Nefecon (budesonide) to the US Food and Drug Administration (FDA), a new oral formulation that targets down-regulation of IgA1 for the treatment of primary IgA.
-
Organ-like studies have revealed how coronavirus attacks the human body
Time of Update: 2020-11-27
new coronavirus can destroy laboratory-cultured lung, liver and kidney tissue, pictured is an in-body culture of human liver duct cells after infection, which can help people understand some of the serious complications caused by the virus.
-
Howson Pharmaceuticals went to Hong Kong to list, spirit, anti-tumor drugs in the domestic leading
Time of Update: 2020-08-16
and anti-tumor product line, Howson Pharmaceuticals is mainly in the treatment of high incidence of solid tumors and relatively limited treatment options of blood tumors, is China's fourth largest anti-tumor pharmaceutical company, the market share is currently 2.5%.
HS-10296 is the third-generation molecular targeting drug developed by Howson to treat lung cancer.
-
Anti anxiety drugs that cause weight loss
Time of Update: 2020-04-03
The fast-paced lifestyle makes anxiety disorder more and more common in modern society Antianxiety drugs are sometimes used as part of the treatment of anxiety disorders These drugs can change the lev
-
New antipsychotic drugs! Alks3831 (olanzapine / samidorphan) is under review in the United States for the treatment of schizophrenia and bipolar I disorder
Time of Update: 2020-01-29
January 29, 2020 / BIOON / -- Alkermes is a fully integrated Irish biopharmaceutical company dedicated to the development of innovative drugs for the treatment of central nervous system (CNS) diseases
-
Scientists from Jilin University extracted effective components of anti gout from sunflower flower disk
Time of Update: 2018-07-07
July 4, the reporter recently learned from Jilin University that Liu Xiaobo, a professor in the school of life sciences of Jilin University, extracted the effective anti gout ingredients from sunflowe
